Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Sell
39
CRL Quote, Financials, Valuation and Earnings
Last price:
$119.48
Seasonality move
:
8.48%
Day range:
$117.13 - $120.89
52-week range:
$91.86 - $254.15
Dividend yield:
0%
P/E ratio:
796.27x
P/S ratio:
1.52x
P/B ratio:
1.76x
Volume:
970.6K
Avg. volume:
2M
1-year change:
-48.84%
Market cap:
$6.1B
Revenue:
$4B
EPS (TTM):
$0.15
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
$941.9M | $2.07 | -7.03% | 62.14% | $151.94 |
|
DVA
DaVita
|
$3.2B | $2.02 | 4.79% | -20.27% | $164.57 |
|
JNJ
Johnson & Johnson
|
$21.6B | $2.58 | 1.79% | 38.86% | $170.19 |
|
LLY
Eli Lilly and
|
$12.7B | $3.46 | 26.43% | 67.37% | $981.63 |
|
RMD
ResMed
|
$1.3B | $2.36 | 8.17% | 24.05% | $264.49 |
|
UNH
UnitedHealth Group
|
$111.6B | $7.29 | 13.45% | 40.56% | $552.84 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
$119.44 | $151.94 | $6.1B | 796.27x | $0.00 | 0% | 1.52x |
|
DVA
DaVita
|
$141.57 | $164.57 | $11.3B | 13.18x | $0.00 | 0% | 0.96x |
|
JNJ
Johnson & Johnson
|
$155.00 | $170.19 | $372.9B | 17.24x | $1.24 | 3.2% | 4.21x |
|
LLY
Eli Lilly and
|
$821.46 | $981.63 | $737.5B | 66.84x | $1.50 | 0.66% | 15.14x |
|
RMD
ResMed
|
$239.95 | $264.49 | $35.2B | 26.93x | $0.53 | 0.86% | 7.05x |
|
UNH
UnitedHealth Group
|
$399.92 | $552.84 | $364B | 16.75x | $2.10 | 2.1% | 0.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
39.29% | 0.935 | 23.61% | 0.92x |
|
DVA
DaVita
|
98.73% | 2.041 | 67.41% | 1.14x |
|
JNJ
Johnson & Johnson
|
40.08% | 0.200 | 13.1% | 0.96x |
|
LLY
Eli Lilly and
|
70.96% | 0.813 | 5.19% | 0.57x |
|
RMD
ResMed
|
10.82% | 0.505 | 2.05% | 1.99x |
|
UNH
UnitedHealth Group
|
44.63% | 1.107 | 16.81% | 0.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
$284.2M | $47.3M | 0.36% | 0.6% | -18.81% | $83.7M |
|
DVA
DaVita
|
$1.1B | $480.7M | 8.12% | 38.64% | 16.77% | $377M |
|
JNJ
Johnson & Johnson
|
$14.5B | $6.3B | 19.44% | 30.18% | 63.19% | $3.4B |
|
LLY
Eli Lilly and
|
$10.5B | $5.4B | 24.21% | 78.25% | 29.07% | -$1.6B |
|
RMD
ResMed
|
$766.4M | $426.3M | 22.47% | 25.76% | 33% | $554.9M |
|
UNH
UnitedHealth Group
|
$23.8B | $9.1B | 12.37% | 21.74% | 8.31% | $4.6B |
Charles River Laboratories International vs. Competitors
-
Which has Higher Returns CRL or DVA?
DaVita has a net margin of -21.29% compared to Charles River Laboratories International's net margin of 7.87%. Charles River Laboratories International's return on equity of 0.6% beat DaVita's return on equity of 38.64%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International28.35% -$4.22 $5.7B DVADaVita32.46% $3.09 $11.5B -
What do Analysts Say About CRL or DVA?
Charles River Laboratories International has a consensus price target of $151.94, signalling upside risk potential of 27.21%. On the other hand DaVita has an analysts' consensus of $164.57 which suggests that it could grow by 16.25%. Given that Charles River Laboratories International has higher upside potential than DaVita, analysts believe Charles River Laboratories International is more attractive than DaVita.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International1 16 1 DVADaVita1 8 0 -
Is CRL or DVA More Risky?
Charles River Laboratories International has a beta of 1.500, which suggesting that the stock is 49.995% more volatile than S&P 500. In comparison DaVita has a beta of 1.141, suggesting its more volatile than the S&P 500 by 14.065%.
-
Which is a Better Dividend Stock CRL or DVA?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DaVita offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charles River Laboratories International pays -- of its earnings as a dividend. DaVita pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRL or DVA?
Charles River Laboratories International quarterly revenues are $1B, which are smaller than DaVita quarterly revenues of $3.3B. Charles River Laboratories International's net income of -$213.4M is lower than DaVita's net income of $259.3M. Notably, Charles River Laboratories International's price-to-earnings ratio is 796.27x while DaVita's PE ratio is 13.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.52x versus 0.96x for DaVita. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International1.52x 796.27x $1B -$213.4M DVADaVita0.96x 13.18x $3.3B $259.3M
-
Which has Higher Returns CRL or JNJ?
Johnson & Johnson has a net margin of -21.29% compared to Charles River Laboratories International's net margin of 50.24%. Charles River Laboratories International's return on equity of 0.6% beat Johnson & Johnson's return on equity of 30.18%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International28.35% -$4.22 $5.7B JNJJohnson & Johnson66.4% $4.54 $130.4B -
What do Analysts Say About CRL or JNJ?
Charles River Laboratories International has a consensus price target of $151.94, signalling upside risk potential of 27.21%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 9.8%. Given that Charles River Laboratories International has higher upside potential than Johnson & Johnson, analysts believe Charles River Laboratories International is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International1 16 1 JNJJohnson & Johnson8 12 0 -
Is CRL or JNJ More Risky?
Charles River Laboratories International has a beta of 1.500, which suggesting that the stock is 49.995% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.
-
Which is a Better Dividend Stock CRL or JNJ?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.2% to investors and pays a quarterly dividend of $1.24 per share. Charles River Laboratories International pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or JNJ?
Charles River Laboratories International quarterly revenues are $1B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Charles River Laboratories International's net income of -$213.4M is lower than Johnson & Johnson's net income of $11B. Notably, Charles River Laboratories International's price-to-earnings ratio is 796.27x while Johnson & Johnson's PE ratio is 17.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.52x versus 4.21x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International1.52x 796.27x $1B -$213.4M JNJJohnson & Johnson4.21x 17.24x $21.9B $11B
-
Which has Higher Returns CRL or LLY?
Eli Lilly and has a net margin of -21.29% compared to Charles River Laboratories International's net margin of 21.68%. Charles River Laboratories International's return on equity of 0.6% beat Eli Lilly and's return on equity of 78.25%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International28.35% -$4.22 $5.7B LLYEli Lilly and82.53% $3.06 $54.4B -
What do Analysts Say About CRL or LLY?
Charles River Laboratories International has a consensus price target of $151.94, signalling upside risk potential of 27.21%. On the other hand Eli Lilly and has an analysts' consensus of $981.63 which suggests that it could grow by 19.5%. Given that Charles River Laboratories International has higher upside potential than Eli Lilly and, analysts believe Charles River Laboratories International is more attractive than Eli Lilly and.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International1 16 1 LLYEli Lilly and15 3 1 -
Is CRL or LLY More Risky?
Charles River Laboratories International has a beta of 1.500, which suggesting that the stock is 49.995% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.
-
Which is a Better Dividend Stock CRL or LLY?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Charles River Laboratories International pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or LLY?
Charles River Laboratories International quarterly revenues are $1B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Charles River Laboratories International's net income of -$213.4M is lower than Eli Lilly and's net income of $2.8B. Notably, Charles River Laboratories International's price-to-earnings ratio is 796.27x while Eli Lilly and's PE ratio is 66.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.52x versus 15.14x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International1.52x 796.27x $1B -$213.4M LLYEli Lilly and15.14x 66.84x $12.7B $2.8B
-
Which has Higher Returns CRL or RMD?
ResMed has a net margin of -21.29% compared to Charles River Laboratories International's net margin of 28.26%. Charles River Laboratories International's return on equity of 0.6% beat ResMed's return on equity of 25.76%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International28.35% -$4.22 $5.7B RMDResMed59.33% $2.48 $6.2B -
What do Analysts Say About CRL or RMD?
Charles River Laboratories International has a consensus price target of $151.94, signalling upside risk potential of 27.21%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 10.23%. Given that Charles River Laboratories International has higher upside potential than ResMed, analysts believe Charles River Laboratories International is more attractive than ResMed.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International1 16 1 RMDResMed8 6 1 -
Is CRL or RMD More Risky?
Charles River Laboratories International has a beta of 1.500, which suggesting that the stock is 49.995% more volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.
-
Which is a Better Dividend Stock CRL or RMD?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.86% to investors and pays a quarterly dividend of $0.53 per share. Charles River Laboratories International pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or RMD?
Charles River Laboratories International quarterly revenues are $1B, which are smaller than ResMed quarterly revenues of $1.3B. Charles River Laboratories International's net income of -$213.4M is lower than ResMed's net income of $365M. Notably, Charles River Laboratories International's price-to-earnings ratio is 796.27x while ResMed's PE ratio is 26.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.52x versus 7.05x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International1.52x 796.27x $1B -$213.4M RMDResMed7.05x 26.93x $1.3B $365M
-
Which has Higher Returns CRL or UNH?
UnitedHealth Group has a net margin of -21.29% compared to Charles River Laboratories International's net margin of 5.74%. Charles River Laboratories International's return on equity of 0.6% beat UnitedHealth Group's return on equity of 21.74%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International28.35% -$4.22 $5.7B UNHUnitedHealth Group21.7% $6.85 $186.4B -
What do Analysts Say About CRL or UNH?
Charles River Laboratories International has a consensus price target of $151.94, signalling upside risk potential of 27.21%. On the other hand UnitedHealth Group has an analysts' consensus of $552.84 which suggests that it could grow by 38.24%. Given that UnitedHealth Group has higher upside potential than Charles River Laboratories International, analysts believe UnitedHealth Group is more attractive than Charles River Laboratories International.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International1 16 1 UNHUnitedHealth Group18 3 0 -
Is CRL or UNH More Risky?
Charles River Laboratories International has a beta of 1.500, which suggesting that the stock is 49.995% more volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.865%.
-
Which is a Better Dividend Stock CRL or UNH?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 2.1% to investors and pays a quarterly dividend of $2.10 per share. Charles River Laboratories International pays -- of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or UNH?
Charles River Laboratories International quarterly revenues are $1B, which are smaller than UnitedHealth Group quarterly revenues of $109.6B. Charles River Laboratories International's net income of -$213.4M is lower than UnitedHealth Group's net income of $6.3B. Notably, Charles River Laboratories International's price-to-earnings ratio is 796.27x while UnitedHealth Group's PE ratio is 16.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.52x versus 0.90x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International1.52x 796.27x $1B -$213.4M UNHUnitedHealth Group0.90x 16.75x $109.6B $6.3B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is RTX The Best Growth Stock?
Among the worldwide aerospace and defense markets, the US controls…
Is VFS Stock Cheap to Buy Now?
VinFast Auto (NASDAQ:VFS) is a leading EV manufacturer in Vietnam.…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
86
TRUP alert for May 6
Trupanion [TRUP] is down 0.38% over the past day.
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 53.44% over the past day.
Sell
35
XYZ alert for May 6
Block [XYZ] is up 0.19% over the past day.
